Eventually, DMXAA was shown to be a STING agonist capable of significant immune-related tumor regression in vivo (Corrales et al., 2015), although it is notable for several disappointing clinical trials (Hines et al., 2023), attributed to its binding of STING in mice, but not humans (Conlon et al., 2013). This evidence concerns the gene STING1 and neoplasm.